Onabotulinum toxin A in children with refractory idiopathic overactive bladder: Medium term outcomes
Tristetraprolin is a prognostic biomarker for poor outcomes among patients with low-grade prostate cancer
A prospective study of aspirin use and prostate cancer risk by TMPRSS2:ERG status
3 reasons to join M3 India Market Research Panel
- Contribute to improvements in Healthcare by sharing your insights
- Earn rewards in your free time
- Secure: We never share your personal information without your permission
Over 4 million Doctors across 9 countries
trust M3 Group for their daily practice.
M3 India is a Joint Venture between M3 Inc. Japan and Health Care at Home India Pvt. Ltd.
By leveraging internet based technologies, this initiative will expand access to information and enhance communication in the Indian healthcare sector.